Cardioprotection through autophagy: ready for clinical trial?

Autophagy. 2011 Apr;7(4):434-5. doi: 10.4161/auto.7.4.14442. Epub 2011 Apr 1.

Abstract

Interventions that reduce infarct size in animal models have largely failed to improve outcome in patients suffering acute myocardial infarction (MI), or 'heart attack'. Our group recently reported a reduction of infarct size by chloramphenicol treatment in a porcine in vivo model of acute MI, through a mechanism involving the induction of autophagy. Since 2005 several studies have implicated autophagy as a target for cardioprotection.

MeSH terms

  • Animals
  • Anti-Infective Agents / pharmacology
  • Autophagy
  • Chloramphenicol / analogs & derivatives*
  • Chloramphenicol / pharmacology
  • Clinical Trials as Topic
  • Comorbidity
  • Coronary Vessels / pathology
  • Humans
  • Myocardial Infarction / metabolism
  • Myocardial Infarction / pathology*
  • Myocardium / pathology*
  • Placebos
  • Swine
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Infective Agents
  • Placebos
  • Chloramphenicol
  • chloramphenicol succinate